Pharmafile Logo
Pharmafocus logo
Advanced Search

Johnson & Johnson

Showing 15 posts of 137 posts found.

Johnson & Johnson to acquire Shockwave Medical

April 8, 2024
Business Services Cardiology, Johnson & Johnson, Shockwave Medical, acquisition

Johnson & Johnson (J&J) and Shockwave Medical have announced that they have entered into a definitive agreement under which J&J …

News

FDA approves J&J’s Opsynvi for PAH treatment

March 25, 2024
Medical Communications Cardiology, FDA, J&J, Johnson & Johnson, Opsynvi, pulmonary arterial hypertension

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has approved Opsynvi (macitentan and tadalafil) …

News

Johnson & Johnson acquires Ambrx Biopharma for approximately $2bn

March 11, 2024
Business Services ADCs, Ambrx Biopharma, J&J, Johnson & Johnson, Oncology, acquisition

Johnson & Johnson (J&J) has announced that it has successfully completed its acquisition of Ambrx Biopharma in an all-cash merger …

News

FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment

March 4, 2024
Medical Communications FDA, Johnson & Johnson, NSCLC, Oncology, Rybrevant

Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved Rybrevant (amibantamab-vmjw) following a priority …

News

FDA approves Balversa for bladder cancer treatment

January 22, 2024
Medical Communications Balversa, FDA, Johnson & Johnson, Oncology, bladder cancer

Johnson & Johnson (J&J) have announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug …

News

J&J vaccine halted in US due to blood clots

April 14, 2021
Research and Development CDC, COVID-19 vaccine, FDA, Janssen, Johnson & Johnson, pharma, pharma news

The CDC and FDA have recommended a pause in the use of the Johnson & Johnson COVID-19 vaccine in the …

News

J & J to ship up to 400 million vaccines to Africa

March 30, 2021
Manufacturing and Production COVAX, COVID-19, COVID-19 vaccine, Janssen, Johnson & Johnson

Johnson & Johnson has reached an agreement to ship as many as 400 million doses of their COVID-19 vaccine to …

News

Janssen’s multiple sclerosis treatment recommended by EMA

March 29, 2021
Sales and Marketing CHMP, EMA, Janssen, Johnson & Johnson, PONVORY, multiple sclerosis

Janssen’s PONVORY therapy for the treatment of adults with relapsing forms of multiple sclerosis (MS) has been recommended by the …

News

AstraZeneca and J&J COVID-19 vaccines face viral vector shortage

March 25, 2021
Astrazenaca, COVID-19, Johnson & Johnson, Vaccine

Both AstraZeneca and J&J face major manufacturing deficiencies for their recombinant vector COVID-19 vaccines, forcing competition over limited production capacity …

News
Janssen sign

Johnson & Johnson’s arthritis drug shows promising results in Phase III trial

March 16, 2021
Manufacturing and Production Janssen, Johnson & Johnson, PSA, Tremfya, arthritis

Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.

News

J&J’s one-shot COVID-19 vaccine approved by European Commission

March 12, 2021
Medical Communications COVID-19, EMA, Johnson & Johnson

The European Commission has granted Johnson and Johnson’s single-shot COVID-19 vaccine Conditional Marketing Authorisation (CMA), it was announced on Thursday. …

News

FDA approves Johnson & Johnson’s COVID-19 vaccine for emergency use

March 1, 2021
Sales and Marketing COVID-19, Janssen, Johnson & Johnson, vaccines

The FDA has issued emergency use authorisation for Johnson & Johnson’s one-shot COVID-19 vaccine, approving the jab for use in …

News

J&J’s one-shot COVID-19 vaccine submitted to the EU

February 17, 2021
Research and Development COVID, COVID Vaccine, COVID-19, Johnson & Johnson, Vaccine

Johnson & Johnson has applied to the EMA for marketing authorisation of their one-shot COVID-19 vaccine in Europe.

News

Johnson & Johnson’s single-shot COVID-19 vaccine 85% effective

February 1, 2021
Sales and Marketing COVID-19, Johnson & Johnson, vaccines

Johnson & Johnson has announced that its COVID-19 vaccine candidate is 85% effective in preventing serious symptoms of the disease, …

News
000_jjjj

Johnson & Johnson selects lead COVID-19 vaccine candidate and targets September Phase I study

March 31, 2020
Manufacturing and Production . Johnson & Johnson, Johnson & Johnson, Vaccine, coronavirus, coronavirus vaccine

Johnson & Johnson announced that it has selected a candidate for a COVID-19 vaccine from potential constructs it has been …

News

Latest content

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024